Certain chemotherapy drugs and cancer treatments can affect the heart and blood vessels during or after cancer therapy. Cardiac monitoring during chemotherapy is an important part of modern cardio-oncology care and helps detect early changes in heart function before serious complications develop. Regular monitoring allows timely treatment and helps patients continue cancer therapy more safely while protecting long-term heart health.
Some cancer treatments may lead to weakening of the heart muscle, reduction in heart pumping function, heart failure, abnormal heart rhythms, blood pressure changes, valve problems, or increased risk of blood clots. The risk may be higher in patients with previous heart disease, diabetes, hypertension, advanced age, radiation exposure, or those receiving specific chemotherapy or targeted therapies.
Before starting chemotherapy, patients often undergo a baseline cardiac evaluation to assess heart health. This may include ECG, echocardiography, blood pressure assessment, blood investigations, and evaluation of cardiovascular risk factors. Establishing baseline heart function helps doctors compare future changes during treatment and identify early signs of cardiotoxicity.
During chemotherapy, regular monitoring is performed using ECG, echocardiography, strain echocardiography (GLS strain imaging), blood tests, and clinical assessment depending on the type of cancer treatment being used. Strain echocardiography is especially valuable because it can detect subtle heart muscle dysfunction earlier than routine echocardiography. Patients may also be monitored for symptoms such as breathlessness, swelling, palpitations, chest discomfort, or fatigue.
In selected patients, advanced cardiac imaging and nuclear imaging techniques such as PET, SPECT, or MUGA scans may be used for more detailed assessment of heart function, blood flow, or chemotherapy-related cardiac injury. Holter monitoring or ambulatory blood pressure monitoring may also be advised in patients with rhythm disturbances or blood pressure fluctuations during treatment.
If early cardiac changes are detected, treatment plans can often be modified to reduce further heart damage. Some patients may require heart-protective medications, optimization of blood pressure and diabetes control, or closer cardiac follow-up during cancer therapy. Early intervention can help preserve heart function and reduce long-term cardiovascular complications.
Cardiac monitoring during chemotherapy plays a major role in improving the safety of cancer treatment and protecting long-term cardiovascular health. Close coordination between oncologists and cardiologists allows comprehensive care focused on both effective cancer treatment and prevention of cardiac complications.
ESC
